

Sheet

Substitute for form 1449/PTO

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	USSN 10/772,963 (Conf #5299)			
Filing Date	5 February 2004			
First Named Inventor	David P. BINGAMAN et al.			
Art Unit	1624			
Examiner Name				
Attorney Docket Number	2471 119			

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (F known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
134	A1	US- 4,771,042	09/13/1988	Braughler et al.	
	A2	US- 4,853,224	08/01/1989	Wong	
	А3	^{US-} 4,975,537	12/04/1990	Aristoff et al.	
	A4	^{US-} 5,164,188	11/17/1992	Wong	
L	A5	^{US-} 5,378,475	01/03/1995	Smith et al.	
	A6	^{US-} 5,773,019	06/30/1998	Ashton et al.	
	A7	^{US-} 5,869,079	02/09/1999	Wong et al.	
	A8	^{US-} 6,120,789	09/19/2000	Dunn	
	A9	^{US-} 6,413,245	07/02/2002	Yaacobi et al.	
	A10	^{US-} 6,413,540	07/02/2002	Yaacobi	
401	A11	^{US-} 6,416,777	07/09/2002	Yaacobi	
	A12	US-			and the second s
	A13	US-			
	A14	US-			
	A15	US-			
	A16	US-	-		
	A17	US-			
	A18	US-			
_	A19	US-			

		FOREI	GN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
			MM-DD-YYYY			T
	A20					
	A21					П
	A22					\Box
	A23					П
	A24_					П
	A25					П

		// /			1	,
Examiner Signature	(t	inh	reff	Date Considered	9/7	104
APSCA AMAZED A						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov of MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English tanguage Translation is attached.

Transitation is attended.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031 rademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			t of 1995, no persons ar	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
				Application Number	USSN 10/772,963 (Conf#5299)	
				Filing Date	5 February 2004	
			PPLICANT	First Named Inventor	David P. BINGAMAN et al.	
			caseand	Art Unit	1624	
			cossary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	2471 US	

	-		
Examiner Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	_2
number(s), publisher, city and/or country where published.		T ²	
600	81	Crum, et al., "A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment", SCIENCE, 230:1375-1378 (Dec 1985)	
	B2	Folkman J and Ingber DE, "Angiostatic Steroids", ANN. SURG., 206(3):374-383 (1987)	
	В3	Ingber, et al., "A Possible Mechanism for Inhibition of Angiogenesis by Angiostatic Steroids: Induction of Capillary Basement Membrane Dissolution", ENDOCRINOLOGY, 119(4):1768-1775 (1986)	
Sol	B 4	Li, et al., "Angiostatic Steroids Potentiated by Sulphated Cyclodextrin Inhibit Corneal Neovascularization", IOVS, 32(11):2898-2905 (October 1991)	, market
	B5		
	B6		
	B 7		
	В8		
	B9		
	B10		

		/		
Examiner /	10/11	10/1/-	Date	9/7/01
Signature /	1000	74	Considered	1/1/04

^{*}EXAMINER: Initial if reference considered, whether of not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. The will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.